Company Overview

Supratek Pharma Inc. is a Montreal-based company with about 27 employees that was established in 1994. The company generates new drug candidates by providing new therapeutic value to existing drugs and newly discovered drugs and by creating novel therapies in autoimmune, anti-viral and angiogenesis areas. The company has eleven drug candidates in its pipeline to treat various cancers, rheumatoid arthritis, viral diseases and neurological disorders. This product pipeline has been created using Suprateks proprietary Biotransport technology and an information-based combinatorial approach called CombiForm. Suprateks first products to enter clinical trials are SP1049C against refractory breast cancer and as a first line therapy for oesophageal cancers and soft tissue sarcoma; SP1018R that blocks the development of rheumatoid arthritis; and a novel water- soluble formulation of paclitaxel, SP1010C with significantly reduced toxicity.

Additionally, the Company has developed a powerful non-viral gene delivery system. Independent testing by industry leaders has demonstrated that this system is able to increase levels of gene expression by 5-20 fold. Additionally, this system is able to modify biological response by recruiting dendritic cells to the site of administration. Both of these characteristics are considered to be essential for the development of efficacious DNA vaccines.

Technology Overview

Supratek's core technology, BiotransportTM, is based on highly diverse chemistries that allow the creation of compounds for pharmaceutical improvement. These compounds form self-assembled colloid systems that solubilize drugs and act as delivery vehicles within the body. In addition, BiotransportTM carriers selectively sensibilize specific tissues and work as biological response modifiers that allow the delivery of drug payloads to specific tissues and inside cells.

The technology is designed to provide drugs with desirable pharmacological properties, such as drug aqueous solubility, cellular uptake, intracellular trafficking, biodistribution and bioavailability, and improved metabolism rate.

CombiFormTM is Supratek's 'toolbox' for drug formulation optimization using BiotransportTM carrier technology. This toolbox allows Supratek to manage BiotransportTM carrier components in numerous combinations to design optimized carriers to solve a drug compound's specific problem. CombiFormTM is designed to quickly and economically increase the percentage of drug leads that become clinical candidates and to increase their probability of reaching the market.

Supratek is the outright owner of its patents. It's patent estate covers the formulation, composition and use of block copolymers in pharmaceutical applications. Supratek holds nine U. S. patents. Three more have been allowed and 16 applications are pending in the U. S. Corresponding international patents or patent applications have been issued or are pending.

Company Information

Additional Details

Legal Name: Supratek Pharma Inc.

Number of Employees: 27

Contacts

Services

• Biotechnology

Products

• Anti-aids

  SP1093 V - Preclinical

• Anticancer

  SP1049C - Phase I clinical, SP101C - Pre-clinical trials, SP1053C - Pre-clinical trials

• Biotransport Carrier Technology
• Cns

  SP1037B - Feasbility studies

• Gene Therapy

  SP1017CVac - DNA vaccine carrier

• Vegf Antagonist

  SP(V5.2) - site targeted carrier - Feasability studies

Additional Information